Scientists Identify Autoimmune Mechanism Behind Long COVID Fatigue

What Causes the Extreme Fatigue in Long COVID?

Research teams, including immunologist Dr. Akiko Iwasaki's group at Yale School of Medicine, have provided increasingly detailed explanations for why Long COVID fatigue can be so severe and persistent. A landmark 2021 study published in Nature by Iwasaki's team identified a diverse array of autoantibodies in COVID-19 patients — antibodies that mistakenly target the body's own proteins rather than the virus. These autoantibodies targeted cytokines, chemokines, complement components, and cell-surface proteins, disrupting normal immune function and potentially interfering with energy metabolism.

Subsequent research has pointed to mitochondrial dysfunction as a key factor in Long COVID fatigue. Mitochondria are the organelles responsible for producing ATP, the molecule that powers virtually every cellular process in the body. Studies have found evidence of impaired mitochondrial respiration in Long COVID patients, which creates a state of cellular energy deficit that manifests clinically as profound fatigue, exercise intolerance, and cognitive impairment — the hallmark symptoms of Long COVID.

A 2023 study published in Nature by Klein, Iwasaki, and colleagues used deep immune profiling to distinguish Long COVID patients from recovered individuals, identifying specific immune signatures including elevated autoantibody levels and altered T cell populations. Research has found that autoantibody levels often correlate with fatigue severity, helping to explain a long-standing puzzle: why standard blood tests and imaging studies in Long COVID patients often appear normal despite patients reporting devastating fatigue. The identification of these autoimmune signatures provides the first objective biomarkers for Long COVID-associated fatigue.

How Does COVID-19 Trigger This Autoimmune Response?

One proposed mechanism is molecular mimicry — a well-documented phenomenon where structural similarities between a pathogen protein and a human protein cause the immune system to mount a cross-reactive attack against the body's own tissues. Researchers have identified sequence similarities between regions of the SARS-CoV-2 spike protein and various human proteins, which could potentially trigger cross-reactive autoantibody production. This mechanism has been established in other post-infectious autoimmune conditions, including Guillain-Barré syndrome following Campylobacter infection.

Not all COVID-19 survivors develop problematic autoantibodies, and research has identified several risk factors. A 2022 study published in Cell by Su and colleagues found that multiple early factors — including pre-existing autoantibodies, specific viral load levels, Epstein-Barr virus reactivation, and type 2 diabetes — could predict who would develop post-acute COVID-19 sequelae. Genetic susceptibility, particularly certain HLA genotypes already associated with autoimmune conditions, may also play a role, though the specific genetic risk factors for Long COVID autoimmunity are still being mapped.

The immune system's response to SARS-CoV-2 infection involves massive immune activation that can cause collateral tissue damage, releasing self-antigens that further prime autoimmune responses. This 'bystander activation' model, combined with molecular mimicry, may explain why the autoimmune process can become self-sustaining even after the virus is cleared. A 2024 study by Cervia-Hasler and colleagues published in Science demonstrated persistent complement dysregulation and thromboinflammation in active Long COVID, providing further evidence that ongoing immune dysregulation — not lingering virus alone — drives chronic symptoms.

What Treatments Are Being Developed Based on This Discovery?

The identification of autoantibody-mediated mechanisms has opened several therapeutic avenues. Among the most discussed is the potential repurposing of existing anti-CD20 monoclonal antibodies — specifically rituximab — which deplete the B cells responsible for producing pathogenic autoantibodies. Rituximab is already approved for treating autoimmune conditions such as rheumatoid arthritis and certain vasculitides, and case reports and small observational studies have described symptom improvement in some Long COVID patients treated with B cell depletion therapy. However, large-scale randomized controlled trial data are not yet available.

The NIH's RECOVER initiative and several academic medical centers have been studying or planning clinical trials of immunomodulatory therapies for Long COVID. The development of autoantibody testing as a potential biomarker could enable precision medicine approaches — treating only those patients whose fatigue is driven by autoimmune mechanisms, which should improve efficacy and reduce unnecessary exposure to immunosuppressive therapy. Several trials investigating immune-targeted therapies for Long COVID are in various stages of enrollment and execution.

Beyond B cell depletion, researchers are exploring other targeted approaches. These include therapies aimed at modulating the complement system (based on findings of persistent complement dysregulation), antivirals for patients with evidence of viral persistence, and mitochondrial-protective compounds that could mitigate downstream effects of immune-mediated cellular damage. The researchers caution that while the science is advancing rapidly, patients should not self-treat with immunosuppressive drugs and should discuss emerging treatment options with their physicians. The Long COVID treatment landscape remains an active and evolving area of clinical research.

What Does This Mean for the Millions with Long COVID?

The implications of this research extend far beyond the laboratory. The WHO has estimated that tens of millions of people worldwide have experienced Long COVID, with a 2022 study in JAMA by the Global Burden of Disease Long COVID Collaborators estimating that 144 million people experienced persistent symptom clusters in 2020 and 2021 alone. For the many patients still living with persistent symptoms, the identification of concrete biological mechanisms provides crucial validation. Many Long COVID patients have faced skepticism from healthcare providers, employers, and disability systems due to the absence of objective diagnostic markers. Autoantibody testing that can confirm specific pathological mechanisms has the potential to change that dynamic.

Diagnostically, several research groups are working to develop autoantibody panels into clinical-grade blood tests. However, it is important to note that autoimmune mechanisms likely account for only a subset of Long COVID cases — other mechanisms including viral persistence, microbiome disruption, and reactivation of latent viruses such as Epstein-Barr virus also appear to play significant roles. Long COVID is increasingly understood as a heterogeneous condition with multiple subtypes that may require different diagnostic and therapeutic approaches.

Public health experts emphasize that this research underscores the importance of COVID-19 prevention, including vaccination and updated booster doses. Studies, including work by Al-Aly and colleagues published in Nature Medicine, have shown that vaccination can reduce Long COVID risk by approximately 50%. The autoimmune findings may also have implications for understanding chronic fatigue in other post-infectious conditions, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), where similar autoimmune mechanisms may be operative. Collaborative studies examining potential overlap between Long COVID and ME/CFS immunopathology are now underway at multiple research centers.